Cargando…
Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
Autores principales: | Crane, Harry, Danta, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170279/ https://www.ncbi.nlm.nih.gov/pubmed/37181340 http://dx.doi.org/10.21037/atm-23-205 |
Ejemplares similares
-
Uncovering the mechanism of action of aspirin in HCC chemoprevention
por: Roehlen, Natascha, et al.
Publicado: (2019) -
Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011) -
May an aspirin a day truly take hepatocellular carcinoma away?
por: Giannini, Edoardo G., et al.
Publicado: (2023) -
Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020) -
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
por: Zhang, Ping, et al.
Publicado: (2018)